Physician profile
Stephen B Kelly
NPI 1134167455
$12,517.73
in general payments reported to CMS, 2019-2025
62 companies · $1,515 in 2025
The $1,515 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,297 · 2020: $1,621 · 2021: $2,014 · 2022: $1,760 · 2023: $1,848 · 2024: $1,462 · 2025: $1,515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,825.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,437.44 | 2019-2025 | Relistor |
| Amgen INC. | $956.51 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $740.17 | 2019-2025 | Belbuca, Xtampza |
| Forte Bio-Pharma LLC | $723.43 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Pfizer INC. | $710.17 | 2019-2025 | |
| Intuitive Surgical, INC. | $519.90 | 2019 | |
| Abbvie INC. | $519.28 | 2021-2025 | |
| Horizon Therapeutics Plc | $464.81 | 2019-2022 | |
| Lundbeck LLC | $431.42 | 2021-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $425.27 | 2020-2025 | Ajovy |
| Merck Sharp & Dohme LLC | $380.50 | 2019-2023 | Belsomra |
| Orexo US, INC. | $376.40 | 2019-2023 | Zubsolv |
| Antares Pharma, INC. | $368.24 | 2020-2025 | Xyosted, Tlando |
| Scilex Pharmaceuticals INC. | $357.28 | 2020-2024 | Ztlido |
| Lilly USA, LLC | $276.74 | 2019-2023 | Emgality, Reyvow |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kelly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.